Eversept Partners LP Has $8.37 Million Stock Holdings in Edgewise Therapeutics, Inc. $EWTX

Eversept Partners LP lessened its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 32.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 337,340 shares of the company’s stock after selling 164,894 shares during the period. Eversept Partners LP owned 0.32% of Edgewise Therapeutics worth $8,371,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of EWTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Edgewise Therapeutics by 6.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,776 shares of the company’s stock worth $963,000 after acquiring an additional 2,463 shares during the period. Jones Financial Companies Lllp acquired a new stake in Edgewise Therapeutics during the 1st quarter worth $47,000. Goldman Sachs Group Inc. grew its holdings in Edgewise Therapeutics by 5.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 366,644 shares of the company’s stock worth $8,066,000 after acquiring an additional 19,753 shares during the period. Strs Ohio acquired a new stake in Edgewise Therapeutics during the 1st quarter worth $84,000. Finally, Creative Planning grew its holdings in Edgewise Therapeutics by 29.4% during the 2nd quarter. Creative Planning now owns 16,910 shares of the company’s stock worth $222,000 after acquiring an additional 3,837 shares during the period.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Wall Street Zen cut shares of Edgewise Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Stifel Nicolaus set a $25.00 price target on shares of Edgewise Therapeutics in a research report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Monday, April 20th. Leerink Partners set a $52.00 price target on shares of Edgewise Therapeutics in a research report on Tuesday. Finally, The Goldman Sachs Group lifted their price target on shares of Edgewise Therapeutics from $20.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.30.

Insider Buying and Selling

In related news, CMO Joanne M. Donovan sold 50,000 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $38.57, for a total value of $1,928,500.00. Following the sale, the chief marketing officer directly owned 4,367 shares of the company’s stock, valued at approximately $168,435.19. The trade was a 91.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 83,892 shares of company stock valued at $3,018,216. Insiders own 21.30% of the company’s stock.

Edgewise Therapeutics Stock Up 2.6%

Shares of NASDAQ EWTX opened at $34.82 on Thursday. The stock has a market cap of $3.75 billion, a price-to-earnings ratio of -20.98 and a beta of 0.27. Edgewise Therapeutics, Inc. has a twelve month low of $12.15 and a twelve month high of $40.76. The company’s fifty day moving average is $33.79 and its 200-day moving average is $29.86.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.04. On average, research analysts anticipate that Edgewise Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.